Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.

Abstract

Within a single-institution phase II trial, we investigated the antitumor activity of the Raltitrexed-Oxaliplatin combination as second-line therapy for malignant pleural mesothelioma (MPM). Fourteen patients were enrolled and all were assessable for response. The trial was then closed because chemotherapy, though well tolerated, yielded no objective responses. The best response observed was disease stabilization in 4 patients only (28.57%), while the other 10 patients (71.42%) progressed despite treatment. Median time to progression (TTP) was 8 weeks (average: 9.85, range: 7-20), while median overall survival was just 14 weeks (average: 21.69, range: 9-66+).

• Authors: Camillo Porta, Matteo Zimatore, Lucia Bonomi, Ilaria Imarisio, Chiara Paglino, Andrea Sartore-Bianchi, Luciano Mutti
• Journal: Lung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 48 Issue 3 Pg. 429-34 (Jun 2005) ISSN: 0169-5002 [Print] Ireland
• PMID: 15893013 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)

Chemical References

• Organoplatinum Compounds
• Quinazolines
• Thiophenes
• Oxaliplatin
• raltitrexed

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Female
• Humans
• Infusions, Intravenous
• Male
• Mesothelioma (drug therapy, pathology)
• Middle Aged
• Organoplatinum Compounds (administration & dosage)
• Oxaliplatin
• Pleural Neoplasms (drug therapy, pathology)
• Quinazolines (administration & dosage)
• Thiophenes (administration & dosage)
• Treatment Outcome